Here’s Why You Don’t Bet Against This Dividend King

Markets have delivered plenty of twists lately, with inflation cooling but growth uneven and volatility still lurking around every earnings corner. Smart investors know one truth holds steady: reliable income beats hype every time. 

That is why you should consider owning a healthcare giant that has raised its dividend through recessions, pandemics, and patent cliffs — without missing a beat. Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is a Dividend King that doesn’t just pay; it delivers consistency that lets shareholders sleep soundly while the broader market twists.

A Dividend Legacy Built on 63 Years of Increases

Johnson & Johnson has hiked its dividend for 63 consecutive years, and stands poised to deliver its 64th annual increase when it reports first-quarter 2026 earnings before the market opens on April 14. That track record isn’t luck — it’s the result of disciplined capital allocation across its diversified portfolio of medicines, medical devices, and consumer health products.

Last year, Johnson & Johnson raised its quarterly payout from $1.24 to $1.30 per share, a near-5% increase. The stock now yields 2.14% at an annualized $5.20 per share. Over the past decade, it has delivered 5% compounded annual growth. The payout ratio also sits at a comfortable 46.7%, leaving ample room for reinvestment or further hikes. In short, this isn’t a high-yield trap—it’s a machine built for steady raises for decades to come.

Financial Results That Speak Louder Than Headlines

Let’s look at the numbers that back this up. Johnson & Johnson’s full-year 2025 results showed reported sales of $94.2 billion, up 6% from 2024. Operational growth hit 5.3%, even after accounting for the loss of exclusivity on Stelara. Innovative Medicine alone topped $60 billion in sales for the first time, with 13 brands growing double digits.

Adjusted earnings reached $10.79 per share, an 8.1% increase from the prior year. Free cash flow came in at approximately $19.7 billion, funding $12.4 billion in dividends paid to shareholders and more than $32 billion in R&D plus strategic acquisitions. The balance sheet remains fortress-strong, with net debt around $28 billion against nearly $20 billion in cash and marketable securities.

No matter how you look at it, these figures show a company that generates cash it can afford to share — without stretching.

Stability Wins Out Versus Peers

Investors often chase higher yields elsewhere in healthcare, but Johnson & Johnson stacks up favorably when you compare the full picture. Here’s how it lines up against two key rivals, based on the latest available data:

Pfizer’s sky-high yield comes with real risk — its payout ratio above 100% signals pressure ahead. Merck offers solid growth but lacks Johnson & Johnson’s breadth and decades-long reliability. Johnson & Johnson also trades at a normalized P/E of about 22.45, a reasonable premium for its lower volatility and proven cash generation.

That said, no stock is risk-free. Ongoing litigation and patent expirations remain watch items, but Johnson & Johnson’s diversified pipeline — 28 platforms now generating over $1 billion annually — positions it to navigate those challenges.

Key Takeaway

Don’t bet against this Dividend King. With earnings due April 14 and the 64th dividend increase on the horizon, Johnson & Johnson offers retail investors a rare combination: 2.14% yield today, low payout ratio for future growth, and a business model built to compound wealth quietly. Add it for the income and the peace of mind — your portfolio will thank you.

Contact [email protected] for any questions or corrections.